UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION OFFICE OF ADMINISTRATIVE LAW JUDGES

In the Matter of

Illumina, Inc.,

a corporation, and

and

Docket No. 9401

GRAIL, Inc., a corporation,

Respondents.

RESPONDENTS' SUPPLEMENTAL MOTION TO REOPEN THE RECORD AND ADMIT TWO ADDITIONAL EXHIBITS

Pursuant to 16 C.F.R. § 3.43(b), 3.51(e)(1) and the April 26, 2021 Scheduling Order, Respondents Illumina, Inc. ("Illumina") and GRAIL, LLC ("GRAIL") ("Respondents"), respectfully request that the Court reopen the proceeding to admit RX4065 and RX4066 (the "Additional Exhibits") into evidence. The Additional Exhibits should be admitted because they are relevant, not cumulative and admitting them will not cause undue prejudice to Complaint Counsel. (July 6, 2022 Order on Resps.' Motions to Reopen Evidentiary Record (reopening the record to admit exhibits because they are "relevant, not cumulative", and would not cause undue prejudice to Complaint Counsel); Mar. 10, 2022 Order on Admissibility of Exhibits at 6 (admitting certain Open Offer Exhibits because they were "offered to show additional Open Offer signatories that did not exist at the time of trial" and which did not require "any additional discovery . . . to avoid undue prejudice").

On July 29, 2022, became the eleventh Illumina customer (and putative MCED developer) to sign Illumina's Open Offer (RX4065 (Illumina) at 1), as well as an addendum to the Open Offer to include additional benefits for (RX4066)

(Illumina) at 1.) Up until this point, and in the run-up to trial,	and Illumina had been
unable to come to terms on a supply agreement.	
	Now, nearly a year
after trial began and on the eve of this Court's initial decision,	has decided to sign the
Open Offer.	

The fact that has now signed the Open Offer is a significant development that the Court should consider in determining whether this Transaction is substantially likely to lessen competition. Complaint Counsel must account for the "real world effects" of the Open Offer to show that such alleged competitive harm is likely. *United States v. AT&T Inc. (AT&T II)*, 310 F. Supp. 3d 161, 241 n.51 (D.D.C. 2018), *aff'd (AT&T II)*, 916 F.3d 1029 (D.C. Cir. 2019). Such a showing requires proving that, notwithstanding the Open Offer, Illumina has an incentive and ability to foreclose GRAIL's putative rivals. As Respondents addressed at length in their post-trial papers, the Open Offer addresses, point-by-point, each of the foreclosure concerns raised by Complaint Counsel and customers. (*See* Resps.' Post-Trial Br. at 154–70.) Courts have found similar proposals sufficient to address alleged anticompetitive harm in vertical mergers. *See, e.g., AT&T II*, 916 F.3d at 1042–43 (holding that "Turner Broadcasting's

Turner Broadcasting increased bargaining leverage", the government's primary theory of harm).

signing of the Open Offer is relevant and probative evidence that bears on whether

Illumina has the incentive and ability to foreclose GRAIL's putative rivals, and that yet again reflects customer interest in the manifest benefits and robust protections of the Open Offer.

I. LEGAL STANDARD

Under Commission Rule 3.51(e)(1), at any time from the close of the hearing record until the filing of the initial decision, the Court may reopen the proceeding for the reception of further evidence for good cause shown. 16 C.F.R. § 3.51(e)(1); *see also In re Polypore Int'l, Inc.*, 2009 WL 3775105, at *2 (Oct. 22, 2009). To determine whether to reopen the proceeding under Rule 3.51(e)(1), this Court has considered the same four factors the Commission considers when it must determine whether to reopen proceedings: "(1) whether the moving party can demonstrate due diligence (that is, whether there is a bona fide explanation for the failure to introduce the evidence at trial); (2) the extent to which the proffered evidence is probative; (3) whether the proffered evidence is cumulative; and (4) whether reopening the record would prejudice the non-moving party." *Polypore*, 2009 WL 3775105, at *5 (citing *In re Brake Guard Prods., Inc.*, No. 9277, 125 F.T.C. 138, 248 n.38 (Jan. 15, 1998)).

II. ARGUMENT

A. Respondents Can Demonstrate Due Diligence.

Respondents can demonstrate due diligence in admitting the Additional Exhibits now. Since only signed the Open Offer late last week, Respondents could not have included this exhibit at any earlier time despite their diligence. *See In re Otto Bock HealthCare N. Am., Inc.*, 2018 WL 4627651, at *2 (Sept. 18, 2018) ("Respondent has demonstrated that it could not have included [the additional exhibits] on its Final Proposed Exhibit List by the

[deadline] despite its diligence, and thus has established 'good cause' for adding these exhibits.").

B. The Additional Exhibits Are Probative of the Open Offer's "real world effects" on Alleged Competitive Harm.

The Additional Exhibits are also probative. See 16 C.F.R. § 3.43(b). The Open Offer will "allay any concerns relating to the Transaction, including that Illumina would disadvantage GRAIL's potential competitors after the Transaction by increasing their sequencing prices or by withholding access to Illumina's latest innovations" in NGS. (PX0064 (Illumina) at 1.) Complaint Counsel argues that even though have signed the Open Offer, or signed supply agreements that incorporate elements of the Open Offer, "a mere signature does not mean that the competitive intensity pre-Acquisition has been restored." (CC Post-Trial Br. at 168, n.111.) But the fact that has signed the Open Offer, is relevant evidence showing that Complaint Counsel's concerns about the Open Offer are unfounded and demonstrating sustained customer interest in the Open Offer. As Complaint Counsel emphasized in its post-trial papers,

had signed the Open Offer.


had signed the Open

¹ Complaint Counsel took this position only after

In its pretrial brief, Complaint Counsel had argued that because

Offer, it could not remedy the alleged competitive harm. (CC Pretrial Br. at 5.)

⁴



These are "critical elements for evaluating" Complaint Counsel's claims. *See Polypore*, 2009 WL 3775105, at *6 ("If Daramic has, after the close of the record, potentially lost a significant customer, as proffered by Respondent, such evidence would directly bear on Respondent's market share and power to control prices -- critical elements for evaluating the Section 7 and monopolization charges.").

C. The Additional Exhibits Present New Facts.

The Additional Exhibits are not cumulative. Because did not sign the Open Offer until just last week, the Additional Exhibits present new facts that did not exist at the time of trial. *See United States v. Magleby*, 241 F.3d 1306, 1316 (10th Cir. 2001) ("Evidence is cumulative if repetitive, and if the small increment of probability it adds may not warrant the time spent in introducing it.").

D. The Additional Exhibits Will Not Prejudice Complaint Counsel.

Finally, the admission of the Additional Exhibits will not unfairly prejudice

Complaint Counsel, who took extensive discovery about views of the Open Offer and was able to freely question about the Open Offer and its concerns with the Transaction.

See Otto Bock, 2018 WL 4627651, at *3 (noting that Complaint Counsel would not be prejudiced by admission of additional exhibits when they had elicited testimony about said topic). The Additional Exhibits provide additional relevant context to testimony Complaint Counsel elicited; if a customer has taken the position in Court that the Open Offer is inadequate—as did during the Trial—it is relevant evidence that the customer subsequently agreed to those terms. The Court should not allow Complaint Counsel to avoid these facts simply because the evidence did not manifest until now.

III. CONCLUSION

For the foregoing reasons, Respondents respectfully request that this motion be granted and the Additional Exhibits be admitted.

Dated: August 6, 2022

Respectfully submitted,

/s/ Sharonmoyee Goswami

Christine A. Varney
David R. Marriott
Sharonmoyee Goswami
Jesse M. Weiss
Michael J. Zaken
CRAVATH, SWAINE & MOORE LLP
Worldwide Plaza
825 Eighth Avenue
New York, NY 10019
Telephone: (212) 474-1000
cvarney@cravath.com
dmarriott@cravath.com
sgoswami@cravath.com

Counsel for Respondent Illumina, Inc.

PUBLIC

Michael G. Egge Marguerite M. Sullivan Anna M. Rathbun David L. Johnson LATHAM & WATKINS LLP 555 Eleventh Street NW Suite 1000 Washington, D.C. 20004 Telephone: (202) 637-2200 michael.egge@lw.com

Alfred C. Pfeiffer 505 Montgomery Street Suite 2000 San Francisco, CA 94111-6538 Telephone: (415) 391-0600 al.pfeiffer@lw.com

Counsel for Respondent GRAIL, LLC

UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION OFFICE OF THE ADMINISTRATIVE LAW JUDGES

In the Matter of		
Illumina, Inc.		
a corporation,	Docket No. 9401	
and		
GRAIL, Inc.		
a corporation,		
Respondents.		
[PROPOSED] ORDER		
Upon consideration of Respondents Illumina, Inc. and GRAIL, LLC's ("Respondents")		
Supplemental Motion to Reopen the Record and to Admit into Evidence Two Additional		
Exhibits, it is hereby		
ORDERED, that Respondents' motion is GRANTED, and it is further		
ORDERED, that good cause exists for Respondents to amend its Final Exhibit List and to		
admit RX4065 and RX4066 into evidence.		
Date:		
D. Michael Chappell		
	Chief Administrative Law Judge	

RX4065 FILED IN CAMERA

RX4066 FILED IN CAMERA

CERTIFICATE OF SERVICE

I hereby certify that on August 9, 2022, I filed the foregoing document electronically using the FTC's E-Filing System, which will send notification of such filing to:

> April Tabor Secretary Federal Trade Commission 600 Pennsylvania Ave., NW, Rm. H-113 Washington, DC 20580 ElectronicFilings@ftc.gov

> The Honorable D. Michael Chappell Administrative Law Judge Federal Trade Commission 600 Pennsylvania Ave., NW, Rm. H-110 Washington, DC 20580

I also certify that I caused the foregoing document to be served via email to:

Complaint Counsel

U.S. Federal Trade Commission

Susan Musser

Stephen A. Mohr

Jordan S. Andrew

Sarah Wohl

Stephanie Bovee

Peter Colwell

Eric Edmondson

Paul Frangie

Samuel Fulliton

Lauren Gaskin

David Gonen

James Wells Harrell

Matthew Joseph

Wade D. Lippard

Sebastian Lorigo

Dylan P. Naegele

Joseph Neely

Brian O'Dea

Nicolas Stebinger

Nicholas Widnell

Counsel for Respondent Illumina, Inc.

Cravath, Swaine & Moore LLP

Christine A. Varney David R. Marriott Sharonmoyee Goswami Jesse M. Weiss Michael J. Zaken

Counsel for Respondent GRAIL, LLC

Latham & Watkins LLP

Michael G. Egge Marguerite M. Sullivan Alfred C. Pfeiffer, Jr. Anna M. Rathbun David L. Johnson

August 9, 2022

/s/ Sharonmoyee Goswami
Sharonmoyee Goswami

Counsel for Respondent Illumina, Inc.